[Antacid bifilact and its effectiveness in the treatment of chronic gastroduodenitis and ulcer disease in children].
Antacid bifilact was applied for the first time to the treatment of 30 patients with gastroduodenitis and peptic ulcer. This enabled one to remove the disease clinical manifestations within the shortest time possible, to normalize the acid-forming function of the stomach and upset microecology of the intestine, lysozyme activity of alimentary secretions. The formulation and know how for antacid bifilact, a new dietetic product, are described.
D000293:Adolescent; D000863:Antacids / Q000627:therapeutic use*; D001644:Bifidobacterium; D002648:Child; D002908:Chronic Disease; D004338:Drug Combinations / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000188:drug therapy*; D004382:Duodenitis / Q000188:drug therapy*; D005756:Gastritis / Q000188:drug therapy*; D006801:Humans; D007778:Lactobacillus; D009113:Muramidase / Q000627:therapeutic use*; D019936:Probiotics
D000863:Antacids; D004338:Drug Combinations; D009113:Muramidase
Antatsidnyĭ bifilakt i ego éffektivnost' v terapii khronicheskogo gastroduodenita i iazvennoĭ bolezni u deteĭ.